Laekna (2105.HK) announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120, an internally ...

North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] ...

There's no question that AI systems have accomplished some impressive feats, mastering games, writing text, and generating ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Dementia specialists have pinpointed certain eating habits as potential early indicators of frontotemporal dementia (FTD). As ...

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

为了应对这个难题，市面上出现了各种各样的耳部清洁产品。然而，这些产品对生物膜的抑制效果究竟如何呢？这一直是个未解之谜。带着这个疑问，来自伦敦玛丽女王大学牙科学院口腔免疫生物学与再生医学中心以及法国维克公司（Virbac）的研究人员 Abish S. Stephen、Vanessa Chala 等人，开展了一项意义重大的研究。该研究成果发表在《BMC Veterinary ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

NORTH CHICAGO, IL, USA and HØRSHOLM, Denmark I March 3, 2025 I AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical ...